Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

Subjects completing the HMR 1726D/2001 study are given the opportunity to continue or switch to teriflunomide for 528 weeks or until teriflunomide is commercially available in the country where patient lives; * subjects on Teriflunomide 7 mg or 14 mg continue on the same dose of teriflunomide. * subjects on placebo are randomized to teriflunomide 7 mg or 14 mg. The total study period per subject is 532 weeks or until teriflunomide is commercially available in the country where patient lives, broken up as follows: * Treatment: 528 weeks or until teriflunomide is commercially available in the country where patient lives, * Post-washout follow-up: 4 weeks after last treatment intake.